Glucagonoma natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 13: | Line 13: | ||
'''PROGNOSIS''' | '''PROGNOSIS''' | ||
Glucagonomas are generally slow-growing | Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis. | ||
The most common site of metastasis is the liver, followed by regional lymph nodes, bone, adrenal gland, kidney, and lung. | The most common site of metastasis is the liver, followed by regional lymph nodes, bone, adrenal gland, kidney, and lung. | ||
Line 21: | Line 21: | ||
Once the tumor is metastatic, cure is rarely, | Once the tumor is metastatic, cure is rarely, | ||
Five- and 10-year survival rates for patients undergoing resection of gastroenteropancreatic neuroendocrine tumors | Five- and 10-year survival rates for patients undergoing resection of gastroenteropancreatic neuroendocrine tumors.<ref name="pmid8606627">{{cite journal| author=Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV| title=The glucagonoma syndrome. Clinical and pathologic features in 21 patients. | journal=Medicine (Baltimore) | year= 1996 | volume= 75 | issue= 2 | pages= 53-63 | pmid=8606627 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8606627 }}</ref> | ||
For approximately 60% of these tumors are cancerous, the prognosis of glucagonoma depends on the following: | For approximately 60% of these tumors are cancerous, the prognosis of glucagonoma depends on the following: | ||
*Whether or not the tumor can be removed by surgery | *Whether or not the tumor can be removed by surgery | ||
*The stage of the tumor, the size of the tumor, whether | *The stage of the tumor, the size of the tumor, whether cancer has spread outside the pancreas | ||
*The patient’s general health | *The patient’s general health | ||
*Whether the tumor has just been diagnosed or has recurred | *Whether the tumor has just been diagnosed or has recurred | ||
*The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10 year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis | *The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10-year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis | ||
==References== | ==References== |
Revision as of 20:19, 1 August 2017
Glucagonoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Glucagonoma natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Glucagonoma natural history, complications and prognosis |
FDA on Glucagonoma natural history, complications and prognosis |
CDC on Glucagonoma natural history, complications and prognosis |
Glucagonoma natural history, complications and prognosis in the news |
Blogs on Glucagonoma natural history, complications and prognosis |
Risk calculators and risk factors for Glucagonoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
If left untreated, patients with glucagonoma may progress to develop necrolytic migratory erythema, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia. The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10 year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis.
Natural History
- If left untreated, patients with glucagonoma may progress to develop necrolytic migratory erythema, cheilosis, stomatitis, diarrhea, polyuria, and polydipsia.
- Glucagonoma have a very slow growth rate compared to most malignant tumors.
Prognosis
PROGNOSIS
Glucagonomas are generally slow-growing but are usually advanced by the time of diagnosis.
The most common site of metastasis is the liver, followed by regional lymph nodes, bone, adrenal gland, kidney, and lung.
Age, grade, and distant metastases are the most significant predictors of survival.
Once the tumor is metastatic, cure is rarely,
Five- and 10-year survival rates for patients undergoing resection of gastroenteropancreatic neuroendocrine tumors.[1]
For approximately 60% of these tumors are cancerous, the prognosis of glucagonoma depends on the following:
- Whether or not the tumor can be removed by surgery
- The stage of the tumor, the size of the tumor, whether cancer has spread outside the pancreas
- The patient’s general health
- Whether the tumor has just been diagnosed or has recurred
- The presence of metastasis is associated with a particularly poor prognosis among patients with glucagonoma. The 10-year event free survival rate is less than 51.6% with metastasis and 64.3% without metastasis
References
- ↑ Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996). "The glucagonoma syndrome. Clinical and pathologic features in 21 patients". Medicine (Baltimore). 75 (2): 53–63. PMID 8606627.